Hypercholesterolemia increases coronary endothelial dysfunction, lipid content, and accelerated atherosclerosis after heart transplantation.
Hyperlipidemia may increase endothelial damage and promote accelerated atherogenesis in graft coronary vasculopathy. To study the effects of hypercholesterolemia on coronary endothelial dysfunction, intimal hyperplasia, and lipid content, a porcine model of heterotopic heart transplantation, allowing nonacute rejection without immunosuppressive drugs, was used. A high cholesterol diet was fed to donor and recipient swine 1 month before and after transplantation. The endothelial function of coronary arteries of native and transplanted hearts from cholesterol-fed animals was studied in organ chambers 30 days after implantation and compared with endothelial function in arteries from animals fed a normal diet. The total serum cholesterol increased 3-fold in donors and recipients. Endothelium-dependent relaxations to serotonin, to the alpha(2)-adrenergic agonist UK14,304, and to the direct G-protein activator sodium fluoride were decreased significantly in allografted hearts compared with native hearts from both groups. Relaxations to the calcium ionophore A23187 and bradykinin were decreased significantly in allografts from animals fed the high cholesterol diet. The prevalence of intimal hyperplasia was significantly increased in coronary arteries from hypercholesterolemic swine. There was a significant increase in the lipid content of allograft arteries of hypercholesterolemic recipients. Hypercholesterolemia causes a general coronary endothelial dysfunction, increases the prevalence of intimal hyperplasia, and augments the incorporation of lipids in the vascular wall after heart transplantation. Hyperlipidemia accelerates graft coronary atherosclerosis through its effects on the endothelium.
Perrault
L P
LP
Research Center and Department of Surgery, Montreal Heart Institute, Montreal, Quebec, Canada.
Mahlberg
F
F
Breugnot
C
C
Bidouard
J P
JP
Villeneuve
N
N
Vilaine
J P
JP
Vanhoutte
P M
PM
D000316:Adrenergic alpha-Agonists / Q000494:pharmacology; D000818:Animals; D001161:Arteriosclerosis / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology*; D001692:Biological Transport / Q000187:drug effects; D000068438:Brimonidine Tartrate; D000001:Calcimycin / Q000494:pharmacology; D002118:Calcium / Q000378:metabolism; D008076:Cholesterol, HDL / Q000032:analysis / Q000097:blood; D008078:Cholesterol, LDL / Q000032:analysis / Q000097:blood; D003331:Coronary Vessels / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D004036:Diet, Atherogenic; D015237:Dinoprost / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004730:Endothelium, Vascular / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology*; D004906:Erythrocyte Count; D005260:Female; D016166:Free Radical Scavengers / Q000494:pharmacology; D016027:Heart Transplantation; D006400:Hematocrit; D006454:Hemoglobins; D006937:Hypercholesterolemia / Q000378:metabolism / Q000503:physiopathology*; D006965:Hyperplasia; D007476:Ionophores / Q000494:pharmacology; D008297:Male; D009206:Myocardium / Q000378:metabolism; D011184:Postoperative Period; D011189:Potassium Chloride / Q000494:pharmacology; D011810:Quinoxalines / Q000494:pharmacology; D012701:Serotonin / Q000494:pharmacology; D013552:Swine; D014184:Transplantation, Homologous; D017539:Tunica Intima / Q000378:metabolism / Q000473:pathology; D014664:Vasodilation / Q000187:drug effects / Q000502:physiology
D000316:Adrenergic alpha-Agonists; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D016166:Free Radical Scavengers; D006454:Hemoglobins; D007476:Ionophores; D011810:Quinoxalines; D012701:Serotonin; D000001:Calcimycin; D000068438:Brimonidine Tartrate; D011189:Potassium Chloride; D015237:Dinoprost; D002118:Calcium